Add-on
All NiaHealth tests are processed in Canadian-certified labs, which are highly trusted by the medical community for their accuracy and reliability. Blood and urine samples are collected by licensed medical professionals and processed using state-of-the-art equipment. NiaHealth is SOC2 Type 2 certified.
Cystatin C is a small protein made by nearly all cells in the body. It circulates in the blood and is filtered by the kidneys, which is why it is widely used as a marker of kidney function. Unlike creatinine, cystatin C levels are less affected by muscle mass, diet, and sex. Beyond the kidneys, research shows that cystatin C can also be influenced by other processes in the body, such as cardiovascular disease, diabetes, inflammation, and thyroid function. This makes it not just a kidney marker, but a broader indicator of overall health.
Cystatin C provides the most accurate estimation of kidney function more accurately, especially when combined with creatinine. Your cystatin C level also carries information about your general health, with higher levels being linked to a greater risk of conditions such as cardiovascular disease and diabetes. Studies in large populations have shown that people with elevated cystatin C tend to have a higher likelihood of health complications and an increased overall risk of mortality, even when kidney function is normal. In this way, cystatin C is valuable both as a kidney test and as a marker of broader health risk.
Rather than a single strict cutoff, cystatin C is best thought of as a “continuous marker,” meaning that risk tends to rise gradually as levels increase. Using data from large populations, we have chosen to define an optimal cystatin C level as <0.8 mg/L, indicating the lowest risk of poor health outcomes (Köttgen et al., 2008). Most people will have a level of 0.8-1.12 mg/L, which may indicate that there is room for improvement in some health areas, especially heart and metabolic health. A level of >1.12 mg/L indicates an increased risk of cardiovascular disease, diabetes, and inflammation, and it is recommended that you take efforts to lower your risk factors for these conditions.
Jung, E., Ro, Y. S., Ryu, H. H., Kong, S. Y., Shin, S. D., & Hwang, S. O. (2022). Cystatin C and mortality risk in the general population: systematic review and dose response meta-analysis. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 27(3), 222–229.
Köttgen, A., Selvin, E., Stevens, L. A., Levey, A. S., Van Lente, F., & Coresh, J. (2008). Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 51(3), 385–394.
This information is educational and does not replace medical advice, diagnosis, or treatment. Your results should be interpreted with a qualified healthcare professional in the context of your health history.